Drugs / Pegenzileukin
Pegenzileukin
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04913220 | Jul 2021 → Aug 2023 | melanoma, skin squamous cell carcinoma | Sanofi | Terminated | No outcome recorded Stop: Business |
| Phase 1/2 | NCT04643002 | Jan 2021 → Sep 2027 expected | plasma cell myeloma | Sanofi | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04009681 | Jun 2019 → Dec 2025 | metastatic neoplasm | Synthorx, Inc, a Sanofi company | Terminated | No outcome recorded Stop: Business |
| Phase 25 trials | ||||||
| Phase 2 | NCT05535023 | Aug 2022 → Jul 2023 | oropharynx cancer, squamous cell carcinoma | M.D. Anderson Cancer Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT05104567 | Dec 2021 → Jul 2023 | colorectal cancer, esophageal adenocarcinoma, esophageal squamous cell carcinoma, gastric cancer +1 | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT05179603 | Dec 2021 → Sep 2023 | classic Hodgkin lymphoma, diffuse large B-cell lymphoma | Sanofi | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT05061420 | Oct 2021 → Jul 2023 | head and neck squamous cell carcinoma | Sanofi | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT04914897 | Sep 2021 → Jul 2023 | non-small cell lung carcinoma, pleural mesothelioma | Sanofi | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-04-09 | Sanofi | Results Interim late-breaking clinical data validate not-alpha profile of THOR-707 (SAR444245), Sanofi’s novel investigational IL-2 sanofi.com ↗
In both the combination and monotherapy settings, initial activity was observed, with three confirmed partial responses, which includes patients who have received prior anti-PD-1 therapeutics. |
| 2020-06-23 | Sanofi | Results Sanofi’s virtual R&D Day event to highlight capabilities, platforms, and expertise in disease pathways to deliver potentially transformative treatments to patients sanofi.com ↗
Early biomarker data from a Phase 1 study of THOR-707 showed that the molecule increased tumor-fighting CD8+ T and Natural Killer cells without significantly increasing regulatory T cells and eosinophils. |
All press releases naming this drug 4 releases
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pegenzileukin | “Phase 1/2 study of pegenzileukin, a pegylated recombinant non-alpha IL-2, with cemiplimab for the treatment of advanced unresectable or metastatic skin cancers.” PMID 42173654 ↗ May 2026 |
| Known as | Il-2 variant thor-707 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650426 ↗ |
| Known as | Pegenzileukina | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650426 ↗ |
| Known as | Pegenzileukine | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650426 ↗ |
| Known as | SAR444245 | “Assessing the Clinical Benefit of SAR444245 (THOR-707) With or Without Other Anticancer Therapies” NCT05179603 ↗3“Pegenzileukin (SAR444245), a pegylated non-alpha recombinant human interleukin (IL)-2 variant” PMID 42173654 ↗ May 2026 |
| Known as | Thor-707 | “SAR444245 (Thor-707)” NCT05061420 ↗ |
| Action | Activate | “for activation of effector T cell and natural killer (NK) cell” PMID 42173654 ↗ May 2026 |
| Modality | Protein / enzyme biologic | “a pegylated non-alpha recombinant human interleukin (IL)-2 variant” PMID 42173654 ↗ May 2026 |
| Route | Intravenous | “Pharmaceutical form: solution for intravenous (IV) administration; Route of administration: IV administration” NCT04009681 ↗ |